Latest news
Teclistamab/Talquetamab Hits Record Low HR in Multiple Myeloma - CancerNetworkCancerNetwork · Sun, 02 Aug 2026 16:04:35 GMTTeclistamab-Talquetamab Combo Cuts Myeloma Progression Risk by 89% - The American Journal of Managed CareThe American Journal of Managed Care · Sat, 01 Aug 2026 12:06:54 GMTHigh-risk smoldering myeloma: Early daratumumab challenges watch-and-wait - Vera HealthVera Health · Fri, 31 Jul 2026 14:51:55 GMT